Similar neuroprotective effects from sodium-glucose cotransporter-2 inhibitors and dulaglutide
1. In this target trial emulation study of older adult patients with type 2 diabetes, those who received sodium-glucose cotransporter-2 ...
Tag: SGLT-2 inhibitors
Sodium-glucose cotransporter 2 inhibitor use in patients with type 2 diabetes linked to decreased risk of nephrolithiasis
1. A reduced risk of nephrolithiasis was linked with patients with type 2 diabetes (T2D) initiating sodium-glucose cotransporter 2 inhibitor ...
SGLT2 inhibitors reduce recurrent flares and hospitalizations in patients with gout
1. In this population cohort study, patients with gout who used sodium-glucose cotransporter-2 inhibitors (SGLT2is) experienced fewer recurrent flares than ...
Sodium-glucose cotransporter-2 inhibitors are of intermediate or low economic value in the treatment of heart failure with preserved ejection fraction
1. Sodium-glucose cotransporter-2 inhibitors (SGLT2-I) in combination with standard of care were found to increase quality-adjusted life-years at a cost ...
SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes
1. SGLT2 inhibitors reduced the risk of kidney disease progression by 37% overall, with comparable effects in patients with and ...
#VisualAbstract: Treatment with empagliflozin reduced progression of chronic kidney disease
Click here to read this study in NEJM
Dapagliflozin associated with reduction in cardiovascular mortality due to lower rates of death from heart failure and sudden death – Pooled analysis of DAPA-HF and DELIVER
1. In this pooled analysis of 11,007 patients with heart failure in the DAPA-HF and DELIVER trials, treatment with dapagliflozin ...
#VisualAbstract: Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction
1. Dapagliflozin was shown to reduce the risk of disease progression and cardiovascular death in patients with a mildly reduced ...
SGLT-2 inhibitors provide morbidity and mortality benefits for patients with heart failure
1. SGLT-2 inhibitors reduced time to first hospitalization and cardiovascular death among patients with preserved, mildly reduced, and reduced ejection ...
Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications
1. In this secondary analysis of the DECLARE-TIMI 58 trial, among 17,160 patients, dapagliflozin consistently reduced the risk of cardiovascular ...